Background: A number of studies have demonstrated the efficacy of virtual reality exposure therapy (VRET) in specific phobias, but research in seriously impaired patients with agoraphobia is lacking. In this randomized controlled trial with patients with agoraphobia and panic disorder, VRET and exposure in vivo were compared in terms of outcome and processes involved. Methods: Patients with panic disorder with agoraphobia (n = 55) were randomly assigned to receive 4 sessions of cognitive behavioral therapy (CBT) followed by either 6 sessions of VRET or 6 sessions of exposure in vivo or to a waiting list control condition. Results: Analyses showed that both active treatment packages were significantly more effective than no treatment and that no differences between VRET and exposure in vivo were found in three out of four outcome measures. On the panic disorder severity scale, however, CBT plus exposure in vivo was more effective than CBT plus VRET. The results show clear synchrony of temporal processes involved in VRET and exposure in vivo on weekly avoidance measures and cognitive measures. Further, it was shown that initial changes in agoraphobic cognitions during the CBT phase predicted later changes in agoraphobic avoidance behavior. Conclusion: These data support the notion that therapeutic processes involved might be the same in VRET and exposure in vivo. However, given the slight superiority of exposure in vivo above VRET, the costs involved in the implementation of VRET and the lack of long-term follow-up, VRET cannot yet be recommended for patients with agoraphobia.

Keywords:
Panic disorder, Agoraphobia, Virtual reality exposure therapy, Exposure therapy, Cognitive behavioral therapy, Avoidance, Cognitions
1.
Emmelkamp PMG, Powers MB: Agoraphobia; in Thomas JC, Hersen M (eds): Handbook of Clinical Psychology Competencies. New York, Springer, 2010, pp 723-758.
2.
Meuret AE, Wolitzky-Taylor KB, Twohig MP, Craske MG: Coping skills and exposure therapy in panic disorder and agoraphobia: latest advances and future directions. Behav Ther 2012;43:271-284.
3.
Emmrich A, Beesdo-Baum K, Gloster AT, Knappe S, Höfler M, Arolt V, Deckert J, Gerlach AL, Hamm A, Kircher T, Lang T, Richter J, Ströhle A, Zwanzger P, Wittchen H-U: Depression does not affect the treatment outcome of CBT for panic and agoraphobia: results from a multicenter randomized trial. Psychother Psychosom 2012;81:161-172.
4.
Mitte K: A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia. J Affect Disord 2005;88:27-45.
5.
Sánchez-Meca J, Rosa-Alcázar AI, Marín-Martínez F, Gómez-Conesa A: Psychological treatment of panic disorder with or without agoraphobia: a meta-analysis. Clin Psychol Rev 2010;30:37-50.
6.
Emmelkamp PMG: Behavior therapy with adults; in Lambert M (ed): Bergin & Garfield's Handbook of Behavior Therapy and Behavior Change. New York, Wiley, 2004, pp 396-448.
7.
Meyerbröker K, Emmelkamp PMG: Virtual reality exposure therapy in anxiety disorders: a systematic review of process-and-outcome studies. Depress Anxiety 2010;27:933-944.
8.
Powers MB, Emmelkamp PMG: Virtual reality exposure therapy for anxiety disorders: a meta-analysis. J Anxiety Disord 2008;22:561-569.
9.
Botella C, Garcia-Palacios A, Villa H, Banos RM, Quero S, Alcaniz M, Riva G: Virtual reality exposure in the treatment of panic disorder and agoraphobia: a controlled study. Clin Psychol Psychother 2007;14:164-175.
10.
Hofmann SG, Suvak MK, Barlow DH, Shear MK, Meuret AE, Rosenfeld D: Preliminary evidence for cognitive mediation during cognitive-behavioral therapy of panic disorder. J Consult Clin Psychol 2007;75:374-379.
11.
Cote S, Bouchard S: Cognitive mechanisms underlying virtual reality exposure. Cyberpsychol Behav 2009;12:121-129.
12.
Meyerbröker K, Emmelkamp PMG: Therapeutic processes in virtual reality exposure therapy: the role of cognitions and the therapeutic alliance. J Cyberther Rehab 2008;1:247-257.
13.
Hoffart A, Sexton H, Hedley LM, Martinsen EW: Mechanisms of change in cognitive therapy for panic disorder with agoraphobia. J Behav Ther Exp Psychiatry 2008;39:262-275.
14.
Telch MJ, Brouillard M, Telch CF, Agras WS, Taylor CB: Role of cognitive appraisal in panic-related avoidance. Behav Res Ther 1989;27:373-383.
15.
Smits JA, Powers MB, Cho Y, Telch MJ: Mechanism of change in cognitive-behavioral treatment of panic disorder: evidence for the fear of fear mediational hypothesis. J Consult Clin Psychol 2004;72:646-652.
16.
Teachman BA, Marker CD, Clerkin EM: Catastrophic misinterpretations as a predictor of symptom change during treatment of panic disorder. J Consult Clin Psychol 2010;78:964-973.
17.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4, text rev (DSM-IV-TR). Washington, American Psychiatric Association, 2000.
18.
First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV Axis I Disorders. Washington, American Psychiatric Association, 1990.
19.
Shear MK, Brown TA, Sholomskas DE, Barlow DH, Gorman JM, Woods SW, Cloitre M: Panic Disorder Severity Scale (PDSS). Pittsburgh, Department of Psychiatry, University of Pittsburgh School of Medicine, 1992.
20.
Wuyek LA, Antony MM, McCabe RE: Psychometric properties of the Panic Disorder Severity Scale: clinician-administered and self-report versions. Clin Psychol Psychother 2011;18:234-243.
21.
Chambless DL, Sharpless BA, Rodriguez D, McCarthy KS, Milrod BL, Khalsa SR, Barber JP: Psychometric properties of the Mobility Inventory for agoraphobia: convergent, discriminant, and criterion-related validity. Behav Ther 2011;42:689-699.
22.
Chambless DL, Caputo GC, Bright P, Gallagher R: Assessment of ‘fear of fear' in agoraphobics: the Body Sensations Questionnaire and the Agoraphobic Cognitions Questionnaire. J Consult Clin Psychol 1984;52:1090-1097.
23.
Telch MJ: The Panic Appraisal Inventory. University of Texas, 1987, unpublished manuscript.
24.
Watson JP, Marks IM: Relevant and irrelevant fear in flooding - a crossover study of phobic patients. Behav Ther 1971;2:275-293.
25.
Craske MG, Barlow DH: Mastery of Anxiety and Panic, ed 4. Oxford, Oxford University Press, 2007.
26.
Meyerbröker K, Morina N, Kerkhof GA, Emmelkamp PMG: Virtual reality exposure treatment of agoraphobia: a comparison of CAVE and HMD. Stud Health Technol Inform 2011;167:51-56.
27.
Graham JW, Olchowski AE, Gilreath TD: How many imputations are really needed? Some practical clarifications of multiple imputation theory. Prev Science 2007;8:206-213.
28.
Gloster AT, Wittchen H-U, Einsle F, Lang T,Helbig-Lang S, Fydrich T, Fehm L: Psychological treatment for panic disorder with agoraphobia: a randomized controlled trial to examine the role of therapist-guided exposure in situ in CBT. J Consult Clin Psychol 2011;79:406-420.
29.
Ruwaard J, Broeksteeg J, Schrieken B, Emmelkamp PMG, Lange A: Web-based therapist-assisted cognitive behavioral treatment of panic symptoms: a randomized controlled trial with a three-year follow-up. J Anxiety Disord 2010;24:387-396.
30.
Peter H, Brückner E, Hand I, Rohr W, Rufer M: Treatment outcome of female agoraphobics 3-9 years after exposure in vivo: a comparison with healthy controls. J Behav Ther Exp Psychiatry 2008;39:3-10.
31.
Fava GA, Rafanelli C, Grandi S, Conti S, Ruini C, Mangelli I, Belluardo P: Long-term outcome of panic disorder with agoraphobia treated by exposure. Psychol Med 2001;31:891-898.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.